Status:
TERMINATED
Use of Patient-Controlled Analgesia in Acute Pancreatitis
Lead Sponsor:
Beth Israel Deaconess Medical Center
Conditions:
Acute Pancreatitis
Eligibility:
All Genders
18-65 years
Brief Summary
Acute pancreatitis (AP) represents a critical health concern nationwide, with estimated 274,000 admissions annually and at a cost of 2.6 billion dollars. Current treatment strategies for AP are limite...
Detailed Description
* Investigators will identify patients with AP based on the 2012 revised Atlanta criteria for diagnosis, i.e., AP is diagnosed if 2 out of the following 3 criteria are met: * Acute onset of persistent...
Eligibility Criteria
Inclusion
- Diagnosis of acute pancreatitis confirmed by revised Atlanta criteria
- Admitted to the medical floor within 48 hours of emergency department arrival at Beth Israel Deaconess Medical Center (BIDMC) in Boston, Massachusetts.
- Age 18-65
Exclusion
- Active illicit drug use
- Discharged from the emergency department
- Direct admission to ICU from emergency department
- Known allergy to opioid medications
- Age \<18 or \>65
- Known chronic pain syndrome or concurrent other medical condition with chronic pain
- Active encephalopathy/confusion/delirium/psychiatric illness or any other condition that limits capacity
- Known chronic opioid use
- Renal insufficiency (baseline Creatinine of \>2 and/or acute kidney injury with Creatinine\>3 on admission)
- Known allergy to acetaminophen or hepatic dysfunction otherwise limiting acetaminophen use
Key Trial Info
Start Date :
February 22 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 7 2023
Estimated Enrollment :
7 Patients enrolled
Trial Details
Trial ID
NCT04816877
Start Date
February 22 2022
End Date
December 7 2023
Last Update
November 22 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States, 02215